A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

This early-phase study is testing a new drug called APL-4098, both on its own and in combination with other treatments, in adults with hard-to-treat blood cancers — specifically relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). **You may be eligible if...** - You are 18 or older - You have been diagnosed with relapsed or refractory AML or MDS that has not responded to standard treatments or where standard treatments are not an option - Your white blood cell count is not excessively high - Your overall physical condition and organ function meet minimum requirements (ECOG ≤ 2, weight ≥ 40kg) **You may NOT be eligible if...** - Your blood cancer has responded well to available standard therapies - You are pregnant, planning to become pregnant, or breastfeeding (effective contraception required) - Your organ function does not meet minimum thresholds Talk to your doctor to see if this trial is right for you.